The Cleveland Clinic’s diagnostic or “testing” patents at issue dealt with a process by which an enzyme was measured and correlated against known levels of the enzyme in patients who were healthy or had cardiovascular disease. The Federal Circuit applied the two step Alice analysis, affirming a finding of Section 101 ineligibility and a failure by plaintiff to state a claim of contributory or induced infringement.
The post Federal Circuit says Cleveland Clinic Diagnostic Patents Ineligible Under § 101 appeared first on IPWatchdog.com | Patents & Patent Law.